Oppenheimer & CO Inc Alnylam Pharmaceuticals, Inc. Transaction History

Oppenheimer & CO Inc

$6.42 Billion
Q3 2024

A detailed history of Oppenheimer & CO Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 1,906 shares of ALNY stock, worth $448,977. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,906

Previous 1,716 11.07%

Holding current value

$448,977

Previous $416,000 25.96%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$233.81 - $287.01 $44,423 - $54,531	190 Added 11.07%	1,906 $524,000
Q1 2024 May 06, 2024	SELL	$146.51 - $198.2 $390,156 - $527,806	-2,663 Reduced 60.81%	1,716 $256,000
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $21,197 - $27,519	-140 Reduced 3.1%	4,379 $838,000
Q3 2023 Nov 07, 2023	BUY	$170.77 - $211.65 $15,881 - $19,683	93 Added 2.1%	4,519 $800,000
Q2 2023 Aug 02, 2023	BUY	$185.01 - $212.05 $27,566 - $31,595	149 Added 3.48%	4,426 $840,000
Q1 2023 May 10, 2023	SELL	$182.66 - $235.53 $8,585 - $11,069	-47 Reduced 1.09%	4,277 $856,000
Q4 2022 Feb 07, 2023	BUY	$185.53 - $241.31 $5,751 - $7,480	31 Added 0.72%	4,324 $1.03 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $105,706 - $177,016	-763 Reduced 15.09%	4,293 $859,000
Q2 2022 Aug 08, 2022	BUY	$120.42 - $169.29 $5,298 - $7,448	44 Added 0.88%	5,056 $738,000
Q1 2022 May 12, 2022	BUY	$127.18 - $173.91 $275,853 - $377,210	2,169 Added 76.29%	5,012 $819,000
Q4 2021 Feb 02, 2022	BUY	$159.56 - $209.29 $80,418 - $105,482	504 Added 21.55%	2,843 $482,000
Q4 2020 Feb 11, 2021	BUY	$122.97 - $147.0 $4,795 - $5,733	39 Added 1.7%	2,339 $304,000
Q2 2020 Aug 11, 2020	BUY	$104.21 - $156.44 $239,683 - $359,812	2,300 New	2,300 $341,000

Others Institutions Holding ALNY

# of Institutions

641

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Account

Oppenheimer & CO Inc Alnylam Pharmaceuticals, Inc. Transaction History